Platform adopted by 10 of the top 25 biopharmaceutical companies, by U.S. governmental agencies, and by academic research centers worldwide Organs-on-Chips enable drug developers and researchers to ...

Organ-on-a-chip maker Emulate has launched an upgraded offering for researchers studying inflammatory bowel disease with its tissue model that helps illustrate how immune cells are activated and ...

BOSTON--(BUSINESS WIRE)--Emulate, Inc., a leading provider of next generation in vitro models, today announced the close of an $82 million Series E financing round led by existing investor Northpond ...

Bellevue, WA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- EMulate Therapeutics, a pioneering digital therapeutics company, announces the launch of its community funding round ...

Emulate is the leading provider of next generation in vitro biological models. Researchers use their organ-on-a-chip technology to understand and predict drug response with greater precision and ...

Emulate, Inc., the leading provider of next-generation in vitro Organ-Chip models, today announced the release of its new Chip-R1™ Rigid Chip, designed to minimize drug absorption and enhance ...

Medical device maker Emulate Therapeutics (EMTX) has set terms for a proposed IPO that would raise around $13M. Emulate said in a filing that it is looking to offer 2.5M shares priced between $4 and ...

EMulate Therapeutics, Inc. (EMTX) has filed proposed terms for a $12.5 million IPO of its common stock, according to an amended S-1/A registration statement. The company is developing medical device ...

Emulate, Inc., a leading provider of next-generation in vitro models, today announced that the Brain-Chip is being sent to the International Space Station U.S. National Laboratory (ISS National Lab) ...

EMulate Therapeutics, a 20-year-old Bellevue, Wash.-based company developing radio frequency energy technology to treat a range of diseases, filed to go public Tuesday. The 7-person company, ...